Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938697973> ?p ?o ?g. }
- W2938697973 endingPage "4730" @default.
- W2938697973 startingPage "4716" @default.
- W2938697973 abstract "We report the design, optimization, and biological evaluation of nuclear receptor RORγ inverse agonists as therapeutic agents for prostate cancer treatment. The most potent compound 27 (designated as XY101) exhibited cellular activity with an IC50 value of 30 nM in a cell-based reporter gene assay with good selectivity against other nuclear receptor subtypes. The cocrystal structure of 27 in complex with the RORγ ligand binding domain provided a solid structural basis for its antagonistic mechanism. 27 potently inhibited cell growth, colony formation, and the expression of AR, AR-V7, and PSA. 27 also exhibited good metabolic stability and a pharmacokinetic profile with oral bioavailability of 59% and a half-life of 7.3 h. Notably, 27 demonstrated promising therapeutic effects with significant tumor growth inhibition in a prostate cancer xenograft model in mice. The potent, selective, metabolically stable, and orally available RORγ inverse agonists represent a new class of compounds as potential therapeutics against prostate cancer." @default.
- W2938697973 created "2019-04-25" @default.
- W2938697973 creator A5002028171 @default.
- W2938697973 creator A5012131365 @default.
- W2938697973 creator A5025869715 @default.
- W2938697973 creator A5025958145 @default.
- W2938697973 creator A5028617316 @default.
- W2938697973 creator A5029784389 @default.
- W2938697973 creator A5030871273 @default.
- W2938697973 creator A5035252190 @default.
- W2938697973 creator A5037793935 @default.
- W2938697973 creator A5042626260 @default.
- W2938697973 creator A5042772475 @default.
- W2938697973 creator A5045548513 @default.
- W2938697973 creator A5049406917 @default.
- W2938697973 creator A5055838753 @default.
- W2938697973 creator A5060068655 @default.
- W2938697973 creator A5070812231 @default.
- W2938697973 creator A5071025330 @default.
- W2938697973 creator A5086664284 @default.
- W2938697973 date "2019-04-09" @default.
- W2938697973 modified "2023-10-18" @default.
- W2938697973 title "Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer" @default.
- W2938697973 cites W1512001995 @default.
- W2938697973 cites W1963842907 @default.
- W2938697973 cites W1971126801 @default.
- W2938697973 cites W1979155909 @default.
- W2938697973 cites W1980017607 @default.
- W2938697973 cites W2007172433 @default.
- W2938697973 cites W2022860174 @default.
- W2938697973 cites W2035397440 @default.
- W2938697973 cites W2046666093 @default.
- W2938697973 cites W2050798797 @default.
- W2938697973 cites W2073160834 @default.
- W2938697973 cites W2092338740 @default.
- W2938697973 cites W2109041281 @default.
- W2938697973 cites W2110534364 @default.
- W2938697973 cites W2115908495 @default.
- W2938697973 cites W2119504728 @default.
- W2938697973 cites W2137467802 @default.
- W2938697973 cites W2141422737 @default.
- W2938697973 cites W2142017607 @default.
- W2938697973 cites W2144081223 @default.
- W2938697973 cites W2148643283 @default.
- W2938697973 cites W2154714625 @default.
- W2938697973 cites W2156923287 @default.
- W2938697973 cites W2159211495 @default.
- W2938697973 cites W2163341755 @default.
- W2938697973 cites W2165782799 @default.
- W2938697973 cites W2166918329 @default.
- W2938697973 cites W2168083201 @default.
- W2938697973 cites W2169961966 @default.
- W2938697973 cites W2170544517 @default.
- W2938697973 cites W2171041379 @default.
- W2938697973 cites W2309624507 @default.
- W2938697973 cites W2320427145 @default.
- W2938697973 cites W2335686898 @default.
- W2938697973 cites W2471374517 @default.
- W2938697973 cites W2582692617 @default.
- W2938697973 cites W2620746860 @default.
- W2938697973 cites W2621899512 @default.
- W2938697973 cites W2785940728 @default.
- W2938697973 cites W2791903644 @default.
- W2938697973 cites W2792073240 @default.
- W2938697973 cites W2793481987 @default.
- W2938697973 cites W2802020380 @default.
- W2938697973 cites W2871307427 @default.
- W2938697973 cites W2884925592 @default.
- W2938697973 cites W2888528107 @default.
- W2938697973 cites W2888822846 @default.
- W2938697973 cites W937903590 @default.
- W2938697973 doi "https://doi.org/10.1021/acs.jmedchem.9b00327" @default.
- W2938697973 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30964293" @default.
- W2938697973 hasPublicationYear "2019" @default.
- W2938697973 type Work @default.
- W2938697973 sameAs 2938697973 @default.
- W2938697973 citedByCount "31" @default.
- W2938697973 countsByYear W29386979732019 @default.
- W2938697973 countsByYear W29386979732020 @default.
- W2938697973 countsByYear W29386979732021 @default.
- W2938697973 countsByYear W29386979732022 @default.
- W2938697973 countsByYear W29386979732023 @default.
- W2938697973 crossrefType "journal-article" @default.
- W2938697973 hasAuthorship W2938697973A5002028171 @default.
- W2938697973 hasAuthorship W2938697973A5012131365 @default.
- W2938697973 hasAuthorship W2938697973A5025869715 @default.
- W2938697973 hasAuthorship W2938697973A5025958145 @default.
- W2938697973 hasAuthorship W2938697973A5028617316 @default.
- W2938697973 hasAuthorship W2938697973A5029784389 @default.
- W2938697973 hasAuthorship W2938697973A5030871273 @default.
- W2938697973 hasAuthorship W2938697973A5035252190 @default.
- W2938697973 hasAuthorship W2938697973A5037793935 @default.
- W2938697973 hasAuthorship W2938697973A5042626260 @default.
- W2938697973 hasAuthorship W2938697973A5042772475 @default.
- W2938697973 hasAuthorship W2938697973A5045548513 @default.
- W2938697973 hasAuthorship W2938697973A5049406917 @default.
- W2938697973 hasAuthorship W2938697973A5055838753 @default.
- W2938697973 hasAuthorship W2938697973A5060068655 @default.